The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer.

ABSTRACT: Colorectal cancer is an important cause of morbidity and mortality worldwide. The current treatment landscape includes chemotherapy, targeted therapy, immunotherapy, radiotherapy, and surgery. A key challenge to improving patient outcomes is the significant inter-patient heterogeneity in treatment response. Tumour organoids derived from the patients' tumours via surgically resected or endoscopically biopsied tissue, have emerged as promising models for personalised medicine. This review synthesises the findings, to date, of studies which have explored the efficacy of ex vivo organoid sensitivity testing for predicting treatment response. Most studies have focused on predicting the response to standard-of-care radiotherapy and chemotherapy options. There is strong evidence to support organo

SUBMITTER: Su C 

PROVIDER: S-EPMC9913532 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature